faricimab

targets

all catalysts(5)

News(10)

• Kodiak skyrockets on positive study data for 2 eye drugs
  The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
  biopharma_dive · 4h ago
• Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
  Genentech's agreement with Earendil Labs came the same day its parent company, Roche, inked a cardiometabolic and renal deal with Atavistik Bio for up to $2 billion.
  biospace · 3d ago
• Merck sees pivotal victory for $3B eye disease prospect
  Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion take…
  fiercebiotech · 4d ago
• Roche bets up to $1B to advance next-gen bispecifics with Dualitas
  The partners will focus R&D efforts on immunological and inflammatory conditions using Dualitas’ DualScreen Bispecific Discovery Engine platform.
  biospace · 11d ago
• Roche, Dualitas team up to find bispecific drugs for immune diseases
  Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments.
  biopharma_dive · 11d ago
• Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
  Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.
  fiercebiotech · 11d ago
• EyePoint plummets on pivotal data for main drug
  Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.
  biopharma_dive · 1mo ago
• FDA scientists question Capricor data; Legend CEO steps down
  Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…
  biopharma_dive · 2mo ago
• Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
  Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…
  biospace · 2mo ago
• Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
  Roche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune disea…
  fiercebiotech · 2mo ago